Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sorry typo 'Lancet' obviously.
I just checked Lacet Respiratory on-line and our P2 paper has not been published. There is this interesting heading below stating that all research papers are published within 8 weeks of submission. Paste below.... Spinnaker
Online First
Below are the latest The Lancet Respiratory Medicine articles published online ahead of print
All research papers have been peer-reviewed and published via our fast-track process within 4-8 weeks of submission
Current IssueOnline First
I have just read this thread and thought I would re-post a short thread from yesterday which relates. Started by Tyla.
tyla
Fri 21:25
Posts: 1,063
Price: 166.00
No Opinion
Well a lot of posters were saying they thought a peer review of phase 2 wouldn't make much difference to the sp, well I definitely think it would, maybe we will see this week, I would go as far to say it would make an absolute minimum of 20% difference to the sp in a positive way obviously.
Recommend (6)Report Post
spinnaker
Today 02:26
Posts: 110
Price: 166.00
No Opinion
Tyla
I wasn't totally sure of the process for Peer Review. It seems that the selected journal sends out the study or paper and relevant background research and/or trial/experiment detail to a number of scientists who may or may not be specialists in the field but more importantly are willing to donate their time for free. Once this process is completed then the journal will publish if all Peer Reviewers queries have been addressed and they agree it has sufficient merit to publish. Is that about right anyone?
I googled Peer Review and came up with this interesting article which I think outlines the pros and cons quite succinctly. https://scicomm.plos.org/2018/08/28/is-it-time-for-pre-publication-peer-review-to-die/
My conclusion is that publication in The Lancet will be very positive for the Company and SP and provide some mainstream journalistic interest. It will also give shareholders and others wishing for a successful early stage treatment a lot of hope and probably expectation that the P3 trials will prove successful. At present I am fairly surprised that Synairgen hasn't teamed up with one or more big Pharma but if they can fund and organise the P3 trial successfully and speedily alone it will have a greater impact on current shareholder value.
I wonder whether RM just couldn't negotiate a good enough deal with the dragons and decided to continue alone but with the Company having full control for the moment at least. Maybe 'No deal was better than a bad deal'. This situation obviously informed the placing, open offer, the publication of the asthma trials with AZN and this Peer Review of the P2 trials. The Board has handled the situation with aplomb in my estimation so far.
I have become increasingly positive over the past couple of days and consider the current share price will show a lot of growth over the next three months.
Best of luck and good health to all the great posters and researchers on this board.
Spinnaker
*aren't
The company did put together a presentation for the placing. Experts around the world will also work for big pharma and the regulators who will see the entire dataset. Peer review will come and I do think it will add value however it won't inform the critical path (route to approval/market), which is why the company are making a big thing out of it.
Scinv... from the opening lines in the bio world article..
The global product development pipeline for COVID-19 is now twice as big as for any particular cancer indication, a major disease like Alzheimer’s or any other infectious disease indication
You can't compare previous peer reviews unless your comparing our review to others that also kicked off in June..
Apples are apples and oranges are oranges but an orange takes longer to eat if you have to peel it..
The lancet is around since 1830's and it speaks volumes to me that our mgt team are showing that they know their business, a classy touch...
What benefit would a non-peer reviewed publication have served?
A positive peer review and publication will of course underline the july results. The company's confidence in the quality if their dataset would suggest that they'll also be confident in the peer review. Ultimately though, its going to say something along the lines of, 'this data supports the need for further investigation of SNG001 in the treatment of hoslitalised COVID patients.' Theyre already moving on with a p3 so the P2 peer review, though welcome, is a little academic.
Thanks scinv
A couple of quick points.
Firstly, we don't know how much importance Synairgen placed on the peer review. Having this reviewed and published in August/September would have been great for us shareholders who just want to see the price go up, but it would be meaningless of there was no phase 3 set up or route to production.
I have said before - everything is being done for a reason. The lack of peer review hasn't stopped Synairgen in any way. If the review is published now then it may actually be perfect timing - a reminder for people that here is a hugely effective treatment and wait a minute they are also ready to start producing hundreds of thousands of units and have further data from home trials etc to further prove efficacy.
People will be fighting to sign up for that!
Have you peer reviewed a study before scinv? Intrigued to know how in a 100 person study there isn't much to review.
Scinv, you generally make valid points, but my God, you're so bloody grumpy!
Scinv.....the Lancet would not accept a study/paper for publishing......without positive peer reviews.....hence the delay.
I thought the company tweet was intended to highlight the fact that RM was talking at the Bio conference? https://www.bioworld.com/articles/499587-bio-europe-taking-stock-of-the-covid-19-pipeline
Scinv, did you see the post yesterday that one of the Professors has said that the P2 trial is going to published shortly in the respiratory Lancet? I know you were deeply concerned about this. I hope you will retract your comment that SNG are liars and RM is a crook.
richard was one of 4 panelists one of whom works for gilead...
NEIL MUL****
VP, Government Affairs, EMEA at Gilead Sciences
big event people like fauci were speaking on other days
https://informaconnect.com/bioeurope/speakers/richard-marsden/ click view session
Yesterday CEO Richard Marsden spoke at BIO Europe digital on a panel discussing COVID-19 therapeutics, and on progressing Synairgen’s #SNG001 drug into later stage trials. Access BIO’s #COVID19 therapeutic development tracker here: https://t.co/urIAtk7SGh